Immuneering Corporation (IMRX)
NasdaqGM · USD · Healthcare · Biotechnology
$3.71 (-0.54%) as of
Key statistics
- Market cap
- 240.03M
- Forward P/E
- -2.95
- EPS (TTM)
- -0.9300
- Dividend yield
- 0.00%
- 52-week range
- 3.3800 – 8.4800
- Beta
- 0.46
- Profit margin
- 0.00%
- Analyst target
- $17.17
- Volume
- 579.76k
About Immuneering Corporation
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Cambridge, MA, United States
- Employees
- 57
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.